KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities

Abstract Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease, whose main molecular trait is the MAPK pathway activation due to KRAS mutation, which is present in 90% of cases. The genetic landscape of KRAS wild type PDAC can be divided into three categories. The first is represented by tumor...

Full description

Bibliographic Details
Main Authors: Claudio Luchini, Gaetano Paolino, Paola Mattiolo, Maria L. Piredda, Alessandro Cavaliere, Marina Gaule, Davide Melisi, Roberto Salvia, Giuseppe Malleo, Jae Il Shin, Sarah Cargnin, Salvatore Terrazzino, Rita T. Lawlor, Michele Milella, Aldo Scarpa
Format: Article
Language:English
Published: BMC 2020-10-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
KRAS
BRAF
MSI
dMMR
fusion genes
pancreatic cancer
Online Access:http://link.springer.com/article/10.1186/s13046-020-01732-6

Internet

http://link.springer.com/article/10.1186/s13046-020-01732-6

Similar Items